Navigation Links
Cambrex Reports Third Quarter 2008 Results
Date:11/4/2008

wances and Rebates 1,137 0.6% 1,001 0.5%

Net Sales 183,303 99.4% 181,819 99.5%

Other Revenues 1,792 1.0% 864 0.5%

Net Revenue 185,095 100.4% 182,683 100.0%

Cost of Sales 127,120 69.0% 115,829 63.4%

Gross Profit 57,975 31.4% 66,854 36.6%

Operating Expenses

Selling, General and

Administrative Expenses 31,511 17.0% 36,572 20.1%

Research and Development Expenses 5,945 3.2% 8,623 4.7%

Restructuring Expenses 1,469 0.8% 4,034 2.2%

Strategic Alternative Costs 1,408 0.8% 28,560 15.6%

Total Operating Expenses 40,333 21.8% 77,789 42.6%

Operating Profit/(Loss) 17,642 9.6% (10,935) -6.0%

Other Expenses/(Income):

Interest Expense/(Income), net 2,302 1.3% (1,341) -0.7%

Other Expenses, net 459 0.2% 930 0.5%

Income/(Loss) Before Income Taxes 14,881 8.1% (10,524) -5.8%

Provision for Income Taxes 6,002 3.3% 4,200 2.3%

Income/(Loss) from Continuing

Operations $8,879 4.8% $(14,724) -8.1%

Income from Discontinued

Operations, Net of Tax - 0.0% 223,707 122.4%

Net Income $8,879 4.8% $208,983 114.3%

Basic Earnings/(Loss) per Share

Income/(Loss) from Continuing

Operations $0.31 $(0.52)

Income from Discontinued

Operations, Net of Tax $- $7.83

Net Income $0.31
'/>"/>

SOURCE Cambrex Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 Audacity, ... activation agency and member of the Huntsworth Health Group, ... to its executive team. In her role, Gonzales will ... , “We are incredibly honored to welcome a talent ... Chief and CEO, Gaëtan Fraikin. “She is a proven ...
(Date:12/17/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... as changes to Martine Rothblatt , Ph.D,s compensation ... United Therapeutics announced the promotion of Roger ... and David Zaccardelli , Pharm.D. to Executive Vice ... promotions, Dr. Rothblatt,s title will change from Chairman and ...
(Date:12/17/2014)... 17, 2014 Tigercat Pharma, Inc. today ... evaluating the investigational oral NK-1 receptor antagonist VPD-737 ... chronic itch who are unresponsive or inadequately responsive ... steroids and antihistamines. The primary ... Scale (VAS) itch score from baseline, comparing drug ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that ... with PVM technology , is now available. The ... tool continuously captures high-resolution images under a wide ... prepares a report pairing the most relevant images ... This compelling blend of high resolution images and ...
Breaking Biology Technology:Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... 2011 BioSpecifics Technologies Corp. (NASDAQ: BSTC ... products marketed as XIAFLEX ® in the U.S. ... announced the appointment of  George Gould, Esq., to its ... an attorney, is Principal of George M. Gould, LLC, ...
... 2011  Janssen Biotech, Inc., one of the Janssen Pharmaceutical ... ), announced today that it has executed an agreement ... jointly develop and market the anti-cancer compound, PCI-32765.  A ... are ongoing across a panel of B-cell malignancy disorders, ...
... December 8, 2011 The Joint Management ... (ENPI CBC MED program) has informed Prof Nava ... they will award a contract of up to 2 ... and directed by Hadassah College, will be implemented in ...
Cached Biology Technology:BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 2BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 3BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 4Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765 2Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765 3The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem 2
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
(Date:12/5/2014)... 4, 2014 Increased emphasis on product ... new testing and inspection technologies. The convergence of ... a range of innovative test solutions. This trend ... Y, which is generally more inclined towards communication, ... development strategies of test equipment vendors will cater ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... Adoptive cell transfer (ACT) therapy is used to treat patients ... of the patient's cancer cells, and some of their immune ... of the cancer cells that stimulate the T cells to ... get expanded and re-infused into the patient to mount an ...
... pandemic influenza, a new study reports for the first time ... from poultry to humans. The research appears in the ... available online. , Crossing the species barrier is an important ... potential. Previous studies have focused on the ability of highly ...
... many scientists thought, genetically modified (GM) corn has not ... , After analyzing tens of thousands of seeds from ... Mexico and the United States found no evidence of ... the researchers, said Allison Snow, a professor of evolution, ...
Cached Biology News:First Whole Genome Map of Genetic Variability in Parkinson’s Disease 2Genetically modified maize not found in southern Mexico 2
[5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...
EnzChek cellulase substrate *blue fluorescent, 339/452...
Request Info...
Rubeola (Measles) Antigen Preservative: No Preservatives...
Biology Products: